Company: NDRA
Filing Date: 2025-10-30
Form Type: 8-K
Source: 0001213900-25-103707
Chunk: 0

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01

Entry into a Material Definitive Agreement.

On October 29, 2025, ENDRA Life Sciences Inc.
(the “ Company”) entered into an At-The-Market Issuance Sales Agreement (the “ ATM Agreement”) with Lucid Capital
Markets, LLC, as sales agent (“ Lucid”), pursuant to which the Company may offer and sell, from time to time through Lucid,
shares of its common stock, par value $0.0001 per share, for aggregate gross proceeds of up to $1,750,000 (the “ Shares”).
The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-277058) and the related
prospectus, as supplemented by a prospectus supplement dated October 29, 2025 and filed with the Securities and Exchange Commission on
such date pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “ Securities Act”).

Pursuant to the ATM Agreement, Lucid may sell
the Shares in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities
Act, including sales made directly on or through the Nasdaq Capital Market. The Company and Lucid may also agree for the Company to sell
Shares to Lucid as principal in negotiated transactions, at a purchase price agreed upon by Lucid and the Company. The offer and sale
of the Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the issuance and sale of all of the Shares subject
to the ATM Agreement, (b) the termination of the ATM Agreement by Lucid or the Company pursuant to the terms thereof, or (c) the three-year
anniversary of the date of the ATM Agreement. The Company has no obligation to sell any of the Shares, and may at any time suspend offers
under the Agreement or terminate the Agreement.

The Company has agreed to pay Lucid a commission
of up to 3.0% of the aggregate gross proceeds from any Shares sold by Lucid and to provide Lucid with customary indemnification and contribution
rights, including for liabilities under the Securities Act. The Company also will reimburse Lucid for certain specified expenses in connection
with entering into and maintaining the ATM Agreement. The ATM Agreement contains customary representations and warranties and conditions
to the placements of the Shares pursuant thereto.

A copy of the ATM